

1 **Contributions of mean and shape of blood pressure distribution to global trends and**
2 **variations in raised blood pressure**

3 NCD Risk Factor Collaboration (NCD-RisC)

4 Address correspondence to Majid Ezzati (majid.ezzati@imperial.ac.uk)

5

6 **Abstract**

7 Both shifts in the entire distribution of blood pressure and changes in its high-blood-pressure
8 tail could change the prevalence of raised blood pressure. We pooled 981 population-based
9 studies with 11.6 million participants, and used a generalised linear mixed model, to examine
10 the contributions of the two drivers to worldwide trends in prevalence from 1985-1994 to
11 2005-2016. In 2005-2016, at the same level of population mean SBP and DBP, men and
12 women in south Asia would have the highest prevalence of raised blood pressure, and those
13 in the high-income Asia Pacific region would have the lowest. In most region-sex-age groups
14 where the prevalence of raised blood pressure declined, one half or more of the decline was
15 due to the decline in mean blood pressure. Where prevalence of raised blood pressure
16 increased, the change was entirely driven by increasing mean blood pressure, offset partly by
17 the change in the prevalence-mean association.

18

19 **Introduction**

20 Raised blood pressure, commonly defined as systolic blood pressure (SBP) ≥ 140 mmHg or
21 diastolic blood pressure (DBP) ≥ 90 mmHg, is used to identify high-risk individuals (1-3).
22 Globally, one in four men and one in five women, totalling 1.13 billion adults, had raised
23 blood pressure in 2015 (4). One of the global non-communicable disease (NCD) targets
24 adopted by the World Health Assembly in 2013 is to lower the prevalence of raised blood
25 pressure by 25% compared to its 2010 level by 2025 (5).

26

27 The prevalence of raised blood pressure varies substantially across and within regions and
28 countries, with age-standardised adult prevalence in 2015 ranging from 20% in the high-
29 income Asia Pacific region to 33% in central and eastern Europe for men, and from 11% in
30 the high-income Asia Pacific region to 28% in sub-Saharan Africa for women (4). Prevalence
31 has declined substantially in high-income regions for decades and is also declining in some
32 middle-income regions; it has been stable or has increased in other low- and middle-income
33 regions (4).

34

35 Blood pressure is a multifaceted trait, affected by genes, foetal and early childhood nutrition
36 and growth (6), adiposity (7, 8), diet (especially sodium and potassium intakes) (7, 9, 10),
37 alcohol use (8, 11), smoking (12), physical activity (8, 13), air pollution (14), lead (15), noise
38 (16), psychosocial stress (17), and the use of blood pressure lowering medicines. Changes in
39 some of these factors, for example increase in body-mass index (BMI) and better nutrition in
40 childhood and adolescence, can shift the entire population distribution of blood pressure, and
41 hence change its mean as well as the prevalence of raised blood pressure. In contrast, the use
42 of antihypertensive medicines and lifestyle change to reduce blood pressure in those with
43 elevated levels would reduce the prevalence of raised blood pressure by acting on the high-
44 blood-pressure tail of the distribution, and hence change the shape of the distribution with a
45 relatively small impact on its mean. An important question that can inform strategies for
46 meeting the global target and reducing the burden of raised blood pressure, is to what extent
47 regional differences and changes over time in the prevalence of raised blood pressure are
48 driven by variations in the mean SBP and DBP versus by the shape of the distribution. We
49 used a database of population-based studies with global coverage conducted over three

50 decades to investigate contributions of population mean and high-blood-pressure individuals
51 to worldwide trends and variations in raised blood pressure.

52

53 **Results**

54 We used data from 981 population-based studies with 11,618,576 participants
55 (Supplementary Table 1), of whom 10,630,495 were aged 20-79 years and satisfied the above
56 inclusion criteria. 380 studies were from the high-income western region, 101 each from
57 central and eastern Europe and east and southeast Asia, 98 from central Asia, Middle East
58 and north Africa, 80 from sub-Saharan Africa, 76 each from high-income Asia Pacific and
59 Latin America and the Caribbean, 36 from south Asia and 33 from Oceania. The individual-
60 level data were summarised into 7,600 age-sex specific pairs of mean and prevalence of
61 raised blood pressure.

62

63 The coefficients of the regression models are listed in Supplementary Tables 2 and 3.
64 Together, mean SBP and DBP, decade, age group and region explained most of the variation
65 in the prevalence of raised blood pressure, evidenced by the high pseudo- R^2 statistics of
66 0.952 for women and 0.932 for men.

67

68 The prevalence of raised blood pressure decreased substantially from 1985-1994 to 2005-
69 2016 in the two high-income regions and central and eastern Europe in both men and women
70 across all ages (Figure 2) (4). It also decreased in Latin America and the Caribbean, and
71 central Asia, Middle East and north Africa, and marginally in men in sub-Saharan Africa.
72 Over the same period, mean SBP and mean DBP decreased in these regions and sexes, except
73 in men in sub-Saharan Africa, whose mean SBP and DBP increased, and in men in central
74 Asia, Middle East and north Africa, whose mean SBP and DBP were unchanged. In 2005-

75 2016, the age-standardised prevalence of raised blood pressure in people aged 20-49 years
76 ranged from 4% (95% credible interval: 3%-6%) in the high-income Asia Pacific to 16%
77 (13%-19%) in sub-Saharan Africa in women, and from 14% (11%-17%) in the high-income
78 Asia Pacific to 25% (21%-30%) in central and eastern Europe in men. In those aged 50-79
79 years, the range was from 31% (26%-36%) in high-income Asia Pacific to 56% (52%-61%)
80 in sub-Saharan Africa in women, and from 40% (36%-43%) in the high-income western
81 region to 57% (51%-63%) in central and eastern Europe in men.

82

83 Although in 2005-2016 the ranking of regions in terms of prevalence of raised blood pressure
84 was largely the same as that of the mean, especially for women, inter-region differences in
85 prevalence were not entirely due to those of mean blood pressure. Rather, some regions had
86 an excess prevalence compared to what would be expected based on their mean, and others a
87 lower prevalence compared to what would be expected based on their mean. At the same
88 level of population mean SBP and DBP as that of the world as a whole, men and women in
89 south Asia would have the highest prevalence of raised blood pressure, about 2-4 percentage
90 points higher than the world average in different age and sex groups (Figure 3). Next highest
91 would be in central Asia, Middle East and north Africa, followed by that in Latin America
92 and the Caribbean. In contrast, at the same level of population mean SBP and DBP as that of
93 the world as a whole, high-income Asia Pacific would have the lowest prevalence, followed
94 by central and eastern Europe, with prevalence about 2-4 percentage points lower than the
95 world average across different age and sex groups. The ordering of regions in terms of excess
96 prevalence was similar between men and women.

97

98 In most regions, sex and age groups that experienced a decline in the prevalence of raised
99 blood pressure, the decline in mean blood pressure was the main driver of the decline in

100 prevalence (Figure 4). The main exceptions to this distributional shift were men in sub-
101 Saharan Africa and in central Asia, Middle East and north Africa whose mean blood pressure
102 increased or remained unchanged while prevalence declined slightly. Further, in men in Latin
103 America and the Caribbean, change in prevalence-mean association contributed marginally
104 more to prevalence decline than did the decline in mean blood pressure. Elsewhere, the
105 decline in mean blood pressure accounted for about one half or more of the decline in the
106 prevalence of raised blood pressure, with a larger contribution where mean blood pressure
107 declined more, typically in high-income regions. Change in the prevalence-mean association,
108 which represents change in the high-blood-pressure tail of the distribution, was responsible
109 for the majority of the remainder of change in prevalence, and for its entirety among men in
110 sub-Saharan Africa and in central Asia, Middle East and north Africa. The contribution of
111 change in prevalence-mean association was larger in those aged 50-79 years than in those
112 aged 20-49 years in most regions, especially for women.

113

114 The prevalence of raised blood pressure increased among men and women in Oceania and
115 south Asia, and among women in sub-Saharan Africa and men in east and southeast Asia.
116 The increase was driven entirely by rise in mean blood pressure, offset partly by the change
117 in the prevalence-mean association. Prevalence of raised blood pressure remained largely
118 unchanged among women in east and southeast Asia, due to opposing effects of increasing
119 mean and the decrease brought by the changes in prevalence-mean association.

120

121 **Discussion**

122 We found that the trends and geographical variations in the prevalence of raised blood
123 pressure are largely driven by shifts in the distribution of blood pressure in whole populations,
124 rather than by the shape of the distribution. There was nonetheless contribution from having

125 fewer high-blood-pressure individuals at the same level of population mean SBP and DBP,
126 generally towards lowering the prevalence of raised blood pressure over time, especially in
127 older age groups.

128

129 Rose and Day (18) and Laaser *et al* (19) used data from the Intersalt Study and from
130 population-based studies in Germany, respectively, and found a strong association between
131 prevalence of raised blood pressure and its mean, as we did, but neither analysis had
132 sufficient data to quantify how the association varied in relation to age, time period or region
133 as was done here. An analysis of data from the multi-country MONICA Project (20) found
134 that the upper percentiles of blood pressure distribution changed as much as its mean in some
135 communities, and by a larger amount in others. The authors concluded that the decline in
136 blood pressure is mostly a population phenomenon but there was no detailed quantification of
137 the contribution, especially in relation to age, time period or region as was done here with
138 substantially more data. Downward shifts in the whole blood pressure distribution over time
139 have also been reported in a few high-income countries (21-28), with some studies also
140 finding a larger decline in the upper tail than in the mean of the blood pressure distribution
141 which is consistent with our results.

142

143 The strengths of our study include presenting the first global analysis of how much
144 population mean and high-blood-pressure individuals have contributed to worldwide trends
145 and variations in raised blood pressure, using a large global database with data from different
146 regions and over time, and using methods that allowed the prevalence-mean association to
147 vary by sex, age group, time period and region. Despite using the most comprehensive global
148 collection of population-based studies to date, some regions had limited data, especially early
149 in our analysis period. Further, there have been changes over time in devices used for

150 measuring blood pressure in health surveys, with standard mercury sphygmomanometers
151 replaced by random-zero sphygmomanometers and more recently digital oscillometric
152 devices. These changes are unlikely to have affected our regional comparisons, and would
153 only affect prevalence-mean association over time if they had differential effects at high
154 versus low blood pressure.

155

156 Although we found that changes in the prevalence of raised blood pressure have been mostly
157 due to whole-distribution shifts, the behavioural, nutritional and environmental drivers of this
158 shift remain uncertain. In high-income countries, the decline in blood pressure has occurred
159 despite the rise in BMI (29), which is an established risk factor for high blood pressure, but
160 how the concurrent and at times larger rise in BMI in low- and middle-income countries may
161 be affecting blood pressure is unclear. Salt intake has declined in China (30) and possibly in
162 some high-income countries (31-33), but has not changed in other countries where blood
163 pressure has declined (34-38). Similarly, prevalence of smoking has declined in most high-
164 income countries and in some middle-income countries but remains high or is increasing in
165 other low- and middle-income regions (39). Other potential population-wide drivers of the
166 decline in mean blood pressure which tend to improve with social and economic development
167 include year-round availability of fruits and vegetables, which might increase the amount and
168 regularity of their consumption (40); central heating at home and work which would lower
169 winter blood pressure (41-43); and improvements in early childhood and adolescent nutrition,
170 as seen in greater height in successive birth cohorts when they reach adulthood (44). A role
171 for such distal determinants with life-course impacts is strengthened by the fact that blood
172 pressure is also decreasing in adolescents in high-income countries and possibly some
173 middle-income countries (45-49).

174

175 While these determinants act to lower mean blood pressure, better developed health systems
176 are more effective in identifying and treating high-blood-pressure individuals, which would
177 change the tail of the distribution without a major impact on its mean. The role of treatment
178 in reducing the prevalence of high blood pressure has become increasingly important as
179 clinical guidelines have lowered the threshold for diagnosing and treating hypertension, e.g.,
180 from having a SBP of 160 mmHg or DBP of 95 mmHg in the 1970s (50) to a SBP of 140
181 mmHg or DBP of 90 mmHg now (3, 51). Over time, a larger share of people with raised
182 blood pressure are treated in high-income countries (21, 52-59), and in some middle-income
183 countries (60-65). Further, there has been improvements in effectiveness of treatment over
184 time, leading to better control of those with hypertension. It may also be the case that changes
185 in some risk factors, e.g., lower salt intake, have larger benefits for people whose blood
186 pressure is high compared to those with low blood pressure (9), hence changing the high-
187 blood-pressure tail of the distribution as well as its mean.

188

189 Our results demonstrate that changes in blood pressure both at the population and individual
190 level have contributed to lowering raised blood pressure. What factors have spurred the
191 former over the past few decades, however, remain largely unclear, and may be related to
192 societal changes in nutrition, housing, and health systems arising from social and economic
193 development and technological progress. They also demonstrate the need for data that go
194 beyond identifying the causes of low or high blood pressure, but also help measure how these
195 factors change over time in worldwide populations. Learning about these factors would
196 inform programmes that can help reverse the rise in the prevalence of raised blood pressure
197 or accelerate its decline in low- and middle-income nations, where prevalence remains the
198 highest, more effectively.

199

200 **Methods**

201 *Study design*

202 We first used population-based data to estimate the association between the prevalence of
203 raised blood pressure, defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg, and population mean
204 SBP and DBP among men and women aged 20 to 79 years in nine regions of the world from
205 1985 to 2016. Our statistical model, described below, allowed the prevalence of raised blood
206 pressure *at any level of mean SBP and DBP* to differ by age group, region and time period.
207 We then used the fitted association to estimate the contributions of changes in the population
208 mean blood pressure versus in the shape of its distribution (represented by how the
209 prevalence-mean association varied over region and time) to the changes in the prevalence of
210 raised blood pressure in different regions.

211

212 *Data sources*

213 We used data from NCD Risk Factor Collaboration (NCD-RisC) database, which contains
214 studies that had measured blood pressure in representative samples of the national
215 populations, or of one or more subnational regions and communities. Our methods for
216 identifying and accessing data sources, and the inclusion and exclusion criteria, are described
217 in a recent publication on blood pressure trends (4). Here, we analysed data collected from
218 1985 to 2016 on men and women aged 20-79 years, in 10-year age groups from 20-29 years
219 to 70-79 years. We excluded data points which did not cover complete ten-year age groups,
220 e.g. those in people aged 25-29 years or 60-64 years, to avoid bias in the estimated
221 associations.

222

223 *Statistical methods*

224 We calculated mean SBP, mean DBP and prevalence of raised blood pressure by sex and 10-
225 year age group in each study, taking into account complex survey design and survey sample
226 weights, where relevant. We excluded age-sex groups with <25 participants, because their
227 means and prevalence have larger uncertainty. We then estimated the relationship between
228 the prevalence of raised blood pressure and mean, using a generalised linear mixed model,
229 shown in the equation (where ε is the error term), separately by sex. We used a probit
230 specification because it provided a better fit to the data than a simple linear or logit model.
231 The model included age group (10-year age groups from 20-29 to 70-79) and the decade
232 when the data were collected (1985-1994, 1995-2004 or 2005-2016). We also included
233 interactions between age group and mean blood pressure, between decade and mean blood
234 pressure, and among these three terms, which allowed the prevalence-mean association to
235 vary by age group and over time. We included regional random intercepts to account for the
236 differences in prevalence at any level of mean SBP and DBP by region. The regions, used in
237 previous analyses of cardiometabolic risk factors (4, 44, 66), were: central and eastern Europe;
238 central Asia, Middle East and north Africa; east and southeast Asia; high-income Asia Pacific;
239 high-income western countries; Latin America and the Caribbean; Oceania; south Asia; and
240 sub-Saharan Africa. Countries in each region are listed in Supplementary Table 4. The
241 models were fitted using a probit link function in statistical software R. Goodness of fit of the
242 models was assessed by McFadden's pseudo- R^2 , which represents the proportional reduction
243 in error variance, and is defined as one minus the ratio of the log-likelihood of the model and
244 that of the null model (i.e. an intercept-only model) (67).

245 Prevalence of raised blood pressure

$$246 = \text{Probit}^{-1} (\beta_0 + \beta_1 \text{Mean}_{\text{SBP}} + \beta_2 \text{Mean}_{\text{DBP}} + \beta_3 \text{Age_group} + \beta_4 \text{Decade} \\ 247 + \beta_5 \text{Age_group} \cdot \text{Decade} + \beta_6 \text{Mean}_{\text{SBP}} \cdot \text{Age_group} + \beta_7 \text{Mean}_{\text{DBP}} \cdot \text{Age_group})$$

248 $+ \beta_8 Mean_{SBP} \cdot Decade + \beta_9 Mean_{DBP} \cdot Decade$
 249 $+ \beta_{10} Mean_{SBP} \cdot Age_group \cdot Decade + \beta_{11} Mean_{DBP} \cdot Age_group \cdot Decade$
 250 $+ Random_intercept_{Region} + \varepsilon)$

251 We used the fitted regression to quantify how much differences across regions and changes
 252 over time in the prevalence of raised blood pressure were driven by differences/changes in
 253 mean SBP and DBP, versus by differences/changes in the prevalence-mean association across
 254 region and over time. We first used the age-sex-specific global mean SBP and DBP in 2010
 255 (~mid-point of 2005-2016 period) in the fitted association, and estimated the prevalence of
 256 raised blood pressure by region. The age-sex-specific mean SBP and DBP values were taken
 257 from a recent comprehensive analysis of worldwide trends in blood pressure (4). We report
 258 the differences between the predicted regional raised blood pressure prevalence and that of
 259 the world as a whole. These differences measure how much prevalence would vary across
 260 regions – due to geographical variations in the shape of blood pressure distribution – if they
 261 had the same population mean blood pressure.

262
 263 We then decomposed total change in prevalence of raised blood pressure from 1985-1994 to
 264 2005-2016 into contributions of change in mean SBP and DBP, change in the shape of
 265 prevalence-mean association, and interaction of the two. The contribution of change in mean
 266 was estimated by allowing mean SBP and DBP for each age, sex, and region to change over
 267 time, while keeping the decade variable fixed at 1985-1994. The contribution of change in
 268 association was estimated by setting mean SBP and DBP to their 1990 levels (mid-year of
 269 1985-1994) for each age, sex, and region, and allowing the decade variable to change. The
 270 interaction of the two factors is the difference between total change in prevalence and the

271 sum of the above two components. The three components are schematically shown in Figure
272 1.

273

274 All analyses were done separately for men and women. Results were calculated by 10-year
275 age groups and then aggregated into two age bands, 20-49 years and 50-79 years, by taking
276 weighted average of age-specific results; weights from the WHO standard population were
277 used.

278

279 **Acknowledgements**

280 M.E. was awarded funding to carry out the research from the Wellcome Trust. We thank
281 WHO country and regional offices and World Heart Federation for support in data
282 identification and access.

283

284 **Author contributions**

285 M.E. designed the study and oversaw research. Members of the Country and Regional Data
286 Group collected and reanalysed data, and checked pooled data for accuracy of information
287 about their study and other studies in their country. B.Z. and M.D.C. led data collection. B.Z.
288 and J.B. led the statistical analysis. B.Z. prepared results. Members of the Pooled Analysis
289 and Writing Group collated data, checked all data sources in consultation with the Country
290 and Regional Data Group, analysed pooled data, and prepared results. B.Z. and M.E. wrote
291 the first draft of the report with input from other members of Pooled Analysis and Writing
292 Group. Members of Country and Regional Data Group commented on draft report.

293

294 **Competing financial interests**

295 The authors declare no competing financial interests.



296 **References**

- 297 1. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL,
298 Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR,
299 Chalmers J, Ramirez AJ, Bakris GL, Wang J, et al. Clinical practice guidelines for the management of
300 hypertension in the community: a statement by the American Society of Hypertension and the
301 International Society of Hypertension. *J Clin Hypertens (Greenwich)*. 2014;16(1):14-26.
- 302 2. Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, Damasceno A, Delles C,
303 Gimenez-Roqueplo AP, Hering D, Lopez-Jaramillo P, Martinez F, Perkovic V, Rietzschel ER, Schillaci G,
304 Schutte AE, Scuteri A, Sharman JE, Wachtell K, Wang JG. A call to action and a lifecourse strategy to
305 address the global burden of raised blood pressure on current and future generations: the Lancet
306 Commission on hypertension. *Lancet*. 2016;388(10060):2665-712.
- 307 3. Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo J, Jones D, Materson B, Oparil S,
308 Wright J, Roccella E, National Heart L, Blood Institute Joint National Committee on Prevention DE,
309 Treatment of High Blood P, National High Blood Pressure Education Program Coordinating C. The
310 seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment
311 of high blood pressure: the JNC 7 report. *JAMA*. 2003;289(19):2560-72.
- 312 4. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a
313 pooled analysis of 1479 population-based measurement studies with 19.1 million participants.
314 *Lancet*. 2017;389(10064):37-55.
- 315 5. World Health Organization. Global action plan for the prevention and control of
316 noncommunicable diseases 2013-2020 World Health Organization, Geneva, Switzerland. 2013.
317 Available from: http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf?ua=1.
- 318 6. Victora CG, Adair L, Fall C, Hallal PC, Martorell R, Richter L, Sachdev HS, Maternal, Child
319 Undernutrition Study G. Maternal and child undernutrition: consequences for adult health and
320 human capital. *Lancet*. 2008;371(9609):340-57.
- 321 7. Sacks FM, Campos H. Dietary therapy in hypertension. *N Engl J Med*. 2010;362(22):2102-12.
- 322 8. IOM (Institute of Medicine). A Population-Based Policy and Systems Change Approach to
323 Prevent and Control Hypertension. Washington, DC: The National Academies Press; 2010.
- 324 9. He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure:
325 Cochrane systematic review and meta-analysis of randomised trials. *BMJ*. 2013;346:f1325.
- 326 10. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased
327 potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses.
328 *BMJ*. 2013;346:f1378.
- 329 11. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction
330 in alcohol consumption on blood pressure: a systematic review and meta-analysis. *The Lancet Public
331 Health*. 2017;2(2):e108-e20.
- 332 12. Virdis A, Giannarelli C, Neves MF, Taddei S, Ghiadoni L. Cigarette smoking and hypertension.
333 *Curr Pharm Des*. 2010;16(23):2518-25.
- 334 13. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and
335 meta-analysis. *J Am Heart Assoc*. 2013;2(1):e004473.
- 336 14. Cai Y, Zhang B, Ke W, Feng B, Lin H, Xiao J, Zeng W, Li X, Tao J, Yang Z, Ma W, Liu T.
337 Associations of Short-Term and Long-Term Exposure to Ambient Air Pollutants With Hypertension: A
338 Systematic Review and Meta-Analysis. *Hypertension*. 2016;68(1):62-70.
- 339 15. Navas-Acien A, Schwartz BS, Rothenberg SJ, Hu H, Silbergeld EK, Guallar E. Bone lead levels
340 and blood pressure endpoints: a meta-analysis. *Epidemiology*. 2008;19(3):496-504.
- 341 16. Munzel T, Gori T, Babisch W, Basner M. Cardiovascular effects of environmental noise
342 exposure. *Eur Heart J*. 2014;35(13):829-36.
- 343 17. Gasperin D, Netuveli G, Dias-da-Costa JS, Pattussi MP. Effect of psychological stress on blood
344 pressure increase: a meta-analysis of cohort studies. *Cad Saude Publica*. 2009;25(4):715-26.

- 345 18. Rose G, Day S. The population mean predicts the number of deviant individuals. *BMJ*.
346 1990;301(6759):1031-4.
- 347 19. Laaser U, Breckenkamp J, Ullrich A, Hoffmann B. Can a decline in the population means of
348 cardiovascular risk factors reduce the number of people at risk? *Journal of epidemiology and*
349 *community health*. 2001;55(3):179-84.
- 350 20. Tunstall-Pedoe H, Connaghan J, Woodward M, Tolonen H, Kuulasmaa K. Pattern of declining
351 blood pressure across replicate population surveys of the WHO MONICA project, mid-1980s to mid-
352 1990s, and the role of medication. *BMJ*. 2006;332(7542):629-35.
- 353 21. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ. Trends
354 in the prevalence, awareness, treatment, and control of hypertension in the adult US population.
355 Data from the health examination surveys, 1960 to 1991. *Hypertension*. 1995;26(1):60-9.
- 356 22. Goff DC, Howard G, Russell GB, Labarthe DR. Birth cohort evidence of population influences
357 on blood pressure in the United States, 1887-1994. *Ann Epidemiol*. 2001;11(4):271-9.
- 358 23. Goff DC, Jr., Gillespie C, Howard G, Labarthe DR. Is the obesity epidemic reversing favorable
359 trends in blood pressure? Evidence from cohorts born between 1890 and 1990 in the United States.
360 *Annals of Epidemiology*. 2012;22(8):554-61.
- 361 24. Kastarinen MJ, Nissinen AM, Vartiainen EA, Jousilahti PJ, Korhonen HJ, Puska PM,
362 Tuomilehto. Blood pressure levels and obesity trends in hypertensive and normotensive Finnish
363 population from 1982 to 1997. *J Hypertens*. 2000;18(3):255-62.
- 364 25. Ulmer H, Kelleher CC, Fitz-Simon N, Diem G, Concin H. Secular trends in cardiovascular risk
365 factors: an age-period cohort analysis of 6 98 954 health examinations in 1 81 350 Austrian men and
366 women. *Journal of Internal Medicine*. 2007;261(6):566-76.
- 367 26. Long GH, Simmons RK, Norberg M, Wennberg P, Lindahl B, Rolandsson O, Griffin SJ,
368 Weinehall L. Temporal Shifts in Cardiovascular Risk Factor Distribution. *American Journal of*
369 *Preventive Medicine*. 2014;46(2):112-21.
- 370 27. Hopstock LA, Bonaa KH, Eggen AE, Grimsaard S, Jacobsen BK, Lochen ML, Mathiesen EB,
371 Njolstad I, Wilsgaard T. Longitudinal and Secular Trends in Blood Pressure Among Women and Men
372 in Birth Cohorts Born Between 1905 and 1977: The Tromso Study 1979 to 2008. *Hypertension*.
373 2015;66(3):496-501.
- 374 28. Holmen J, Holmen TL, Tverdal A, Holmen OL, Sund ER, Midthjell K. Blood pressure changes
375 during 22-year of follow-up in large general population - the HUNT Study, Norway. *BMC*
376 *cardiovascular disorders*. 2016;16:94.
- 377 29. NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975
378 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million
379 participants. *Lancet*. 2016;387(10026):1377-96.
- 380 30. Du S, Batis C, Wang H, Zhang B, Zhang J, Popkin BM. Understanding the patterns and trends
381 of sodium intake, potassium intake, and sodium to potassium ratio and their effect on hypertension
382 in China. *Am J Clin Nutr*. 2014;99(2):334-43.
- 383 31. He FJ, Pombo-Rodrigues S, Macgregor GA. Salt reduction in England from 2003 to 2011: its
384 relationship to blood pressure, stroke and ischaemic heart disease mortality. *BMJ Open*.
385 2014;4(4):e004549.
- 386 32. Ikeda N, Gakidou E, Hasegawa T, Murray CJ. Understanding the decline of mean systolic
387 blood pressure in Japan: an analysis of pooled data from the National Nutrition Survey, 1986-2002.
388 *Bull World Health Organ*. 2008;86(12):978-88.
- 389 33. Laatikainen T, Pietinen P, Valsta L, Sundvall J, Reinivuo H, Tuomilehto J. Sodium in the
390 Finnish diet: 20-year trends in urinary sodium excretion among the adult population. *Eur J Clin Nutr*.
391 2006;60(8):965-70.
- 392 34. Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, Engell RE, Lim SS, Danaei G,
393 Mozaffarian D, Global Burden of Diseases N, Chronic Diseases Expert G. Global, regional and national
394 sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary
395 surveys worldwide. *BMJ Open*. 2013;3(12):e003733.

- 396 35. Bernstein AM, Willett WC. Trends in 24-h urinary sodium excretion in the United States,
397 1957-2003: a systematic review. *Am J Clin Nutr.* 2010;92(5):1172-80.
- 398 36. Lee HS, Duffey KJ, Popkin BM. Sodium and potassium intake patterns and trends in South
399 Korea. *J Hum Hypertens.* 2013;27(5):298-303.
- 400 37. Johnson C, Praveen D, Pope A, Raj TS, Pillai RN, Land MA, Neal B. Mean population salt
401 consumption in India: a systematic review. *J Hypertens.* 2017;35(1):3-9.
- 402 38. Sarno F, Claro RM, Levy RB, Bandoni DH, Monteiro CA. [Estimated sodium intake for the
403 Brazilian population, 2008-2009]. *Rev Saude Publica.* 2013;47(3):571-8.
- 404 39. Bilano V, Gilmour S, Moffiet T, d'Espagnet ET, Stevens GA, Commar A, Tuyl F, Hudson I,
405 Shibuya K. Global trends and projections for tobacco use, 1990-2025: an analysis of smoking
406 indicators from the WHO Comprehensive Information Systems for Tobacco Control. *Lancet.*
407 2015;385(9972):966-76.
- 408 40. Micha R, Khatibzadeh S, Shi P, Andrews KG, Engell RE, Mozaffarian D. Global Burden of
409 Diseases N, Chronic Diseases Expert G. Global, regional and national consumption of major food
410 groups in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys
411 worldwide. *BMJ Open.* 2015;5(9):e008705.
- 412 41. Lewington S, Li L, Sherliker P, Guo Y, Millwood I, Bian Z, Whitlock G, Yang L, Collins R, Chen J,
413 Wu X, Wang S, Hu Y, Jiang L, Yang L, Lacey B, Peto R, Chen Z, China Kadoorie Biobank study c.
414 Seasonal variation in blood pressure and its relationship with outdoor temperature in 10 diverse
415 regions of China: the China Kadoorie Biobank. *J Hypertens.* 2012;30(7):1383-91.
- 416 42. Saeki K, Obayashi K, Iwamoto J, Tanaka Y, Tanaka N, Takata S, Kubo H, Okamoto N, Tomioka
417 K, Nezu S, Kurumatani N. Influence of room heating on ambulatory blood pressure in winter: a
418 randomised controlled study. *Journal of epidemiology and community health.* 2013;67(6):484-90.
- 419 43. Wang Q, Li C, Guo Y, Barnett AG, Tong S, Phung D, Chu C, Dear K, Wang X, Huang C.
420 Environmental ambient temperature and blood pressure in adults: A systematic review and meta-
421 analysis. *Sci Total Environ.* 2017;575:276-86.
- 422 44. NCD Risk Factor Collaboration. A century of trends in adult human height. *eLife.*
423 2016;5:e13410.
- 424 45. McCarron P, Smith GD, Okasha M. Secular changes in blood pressure in childhood,
425 adolescence and young adulthood: systematic review of trends from 1948 to 1998. *J Hum Hypertens.*
426 2002;16(10):677-89.
- 427 46. Dong B, Wang Z, Song Y, Wang HJ, Ma J. Understanding trends in blood pressure and their
428 associations with body mass index in Chinese children, from 1985 to 2010: a cross-sectional
429 observational study. *BMJ Open.* 2015;5(9):e009050.
- 430 47. Khang YH, Lynch JW. Exploring determinants of secular decreases in childhood blood
431 pressure and hypertension. *Circulation.* 2011;124(4):397-405.
- 432 48. Chiolero A, Paradis G, Madeleine G, Hanley JA, Paccaud F, Bovet P. Discordant secular trends
433 in elevated blood pressure and obesity in children and adolescents in a rapidly developing country.
434 *Circulation.* 2009;119(4):558-65.
- 435 49. Xi B, Zhang T, Zhang M, Liu F, Zong X, Zhao M, Wang Y. Trends in Elevated Blood Pressure
436 Among US Children and Adolescents: 1999-2012. *Am J Hypertens.* 2016;29(2):217-25.
- 437 50. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High
438 Blood Pressure. A cooperative study. *JAMA.* 1977;237(3):255-61.
- 439 51. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De
440 Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S,
441 Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, et al. 2013 ESH/ESC guidelines for the
442 management of arterial hypertension: the Task Force for the Management of Arterial Hypertension
443 of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur*
444 *Heart J.* 2013;34(28):2159-219.
- 445 52. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of
446 hypertension, 1988-2008. *JAMA.* 2010;303(20):2043-50.

- 447 53. Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U. Hypertension prevalence,
448 awareness, treatment and control in Germany 1998 and 2008-11. *J Hum Hypertens.* 2015;29(4):247-
449 53.
- 450 54. Reklaitiene R, Tamosiunas A, Virviciute D, Baceviciene M, Luksiene D. Trends in prevalence,
451 awareness, treatment, and control of hypertension, and the risk of mortality among middle-aged
452 Lithuanian urban population in 1983-2009. *BMC cardiovascular disorders.* 2012;12:68.
- 453 55. McAlister FA, Wilkins K, Joffres M, Leenen FH, Fodor G, Gee M, Tremblay MS, Walker R,
454 Johansen H, Campbell N. Changes in the rates of awareness, treatment and control of hypertension
455 in Canada over the past two decades. *CMAJ.* 2011;183(9):1007-13.
- 456 56. Cifkova R, Skodova Z, Bruthans J, Adamkova V, Jozifova M, Galovcova M, Wohlfahrt P,
457 Krajcoviechova A, Poledne R, Stavek P, Lanska V. Longitudinal trends in major cardiovascular risk
458 factors in the Czech population between 1985 and 2007/8. *Czech MONICA and Czech post-MONICA.*
459 *Atherosclerosis.* 2010;211(2):676-81.
- 460 57. Kastarinen M, Antikainen R, Peltonen M, Laatikainen T, Barengo NC, Jula A, Salomaa V,
461 Jousilahti P, Nissinen A, Vartiainen E, Tuomilehto J. Prevalence, awareness and treatment of
462 hypertension in Finland during 1982-2007. *J Hypertens.* 2009;27(8):1552-9.
- 463 58. Torma E, Carlberg B, Eriksson M, Jansson JH, Eliasson M. Long term trends in control of
464 hypertension in the Northern Sweden MONICA study 1986-2009. *BMC Public Health.* 2015;15:957.
- 465 59. Sans S, Paluzie G, Balana L, Puig T, Balaguer-Vintro I. [Trends in prevalence, awareness,
466 treatment and control of arterial hypertension between 1986 and 1996: the MONICA-Catalonia
467 study]. *Med Clin (Barc).* 2001;117(7):246-53.
- 468 60. Fasce E, Campos I, Ibanez P, Flores M, Zarate H, Roman O, Fasce F. Trends in prevalence,
469 awareness, treatment and control of hypertension in urban communities in Chile. *J Hypertens.*
470 2007;25(9):1807-11.
- 471 61. Sengul S, Akpolat T, Erdem Y, Derici U, Arici M, Sindel S, Karatan O, Turgan C, Hasanoglu E,
472 Caglar S, Erturk S, Turkish Society of H, Renal D. Changes in hypertension prevalence, awareness,
473 treatment, and control rates in Turkey from 2003 to 2012. *J Hypertens.* 2016;34(6):1208-17.
- 474 62. Hou Z, Meng Q, Zhang Y. Hypertension Prevalence, Awareness, Treatment, and Control
475 Following China's Healthcare Reform. *Am J Hypertens.* 2016;29(4):428-31.
- 476 63. Dorobantu M, Darabont R, Ghiorge S, Arsenescu-Georgescu C, Macarie C, Mitu F, Lighezan
477 D, Musetescu R, Pop C, Ardeleanu E, Craiu E, Tautu OF. Hypertension prevalence and control in
478 Romania at a seven-year interval. Comparison of SEPHAR I and II surveys. *J Hypertens.*
479 2014;32(1):39-47.
- 480 64. Xi B, Liang Y, Reilly KH, Wang Q, Hu Y, Tang W. Trends in prevalence, awareness, treatment,
481 and control of hypertension among Chinese adults 1991-2009. *Int J Cardiol.* 2012;158(2):326-9.
- 482 65. Pilav A, Doder V, Brankovic S. Awareness, Treatment, and control of Hypertension among
483 Adult Population in the Federation of Bosnia and Herzegovina over the Past Decade. *J Public Health*
484 *Res.* 2014;3(3):323.
- 485 66. NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of
486 751 population-based studies with 4.4 million participants. *Lancet.* 2016;387(10027):1513-30.
- 487 67. McFadden D. Conditional Logit Analysis of Qualitative Choice Behavior. In: Zarembka P,
488 editor. *Frontiers in econometrics:* Academic Press; 1974. p. 105-42.



Interaction of the two = Total change - (Contribution of the change in mean blood pressure + Contribution of the change in the association)


489 **Figure 1:** Schematic diagram for the contributions of change in mean blood pressure and in
490 shape of the blood pressure distribution to the change in prevalence of raised blood pressure.

491
492 Each S-shaped curve shows what the prevalence of raised blood pressure would be at
493 different levels of population mean for a specific shape of population distribution. A change
494 in mean without a change in the shape of the distribution (Panel A) would move prevalence
495 along a curve (blue point in Panel D). A change in the shape of the distribution without a
496 change in mean (Panel B) would vertically move prevalence from one curve to another
497 (purple point in Panel D). The combination (Panel C) would move prevalence from one curve
498 to another, as well as along the curve (orange point in Panel D)


499
500 The figure shows the contributions when raised blood pressure is defined based on one blood
501 pressure (either SBP or DBP). The same concept applies when raised blood pressure is
502 defined based on both SBP and DBP.

Women


Prevalence of raised blood pressure (%)




Mean systolic blood pressure (mmHg)




Mean diastolic blood pressure (mmHg)




High-income Asia Pacific




High-income Asia Pacific




High-income Asia Pacific




Oceania



Oceania




Oceania




— 2005–2016 - - - 1985–1994 decrease increase

Men


Prevalence of raised blood pressure (%)



Mean systolic blood pressure (mmHg)




Mean diastolic blood pressure (mmHg)




— 2005–2016 - - - 1985–1994 ■ decrease ■ increase

503 **Figure 2:** Changes in prevalence of raised blood pressure, mean SBP and mean DBP from
504 1985-1994 to 2005-2016 by region for men and women, by age group.



505 **Figure 3:** Regional differences in prevalence of raised blood pressure among men and
506 women aged 20-49 years and 50-79 years in 2005-2016 if every region had the same mean
507 SBP and DBP, equal to the global age-sex-specific mean in 2010.

508



509 **Figure 4:** Contributions of change in mean blood pressure, change in prevalence-mean
510 association, and the interaction of the two, to change in prevalence of raised blood pressure
511 since 1985-1994 by region for men and women aged 20-49 years and 50-79 years.

512 **NCD Risk Factor Collaboration (NCD-RisC)**

513 Pooled Analysis and Writing

514 Bin Zhou (Imperial College London, UK); James Bentham (University of Kent, UK; Imperial
515 College London, UK); Mariachiara Di Cesare (Middlesex University, UK); Honor Bixby
516 (Imperial College London, UK); Goodarz Danaei (Harvard TH Chan School of Public Health,
517 USA); Kaveh Hajifathalian (Cleveland Clinic, USA); Cristina Taddei (Imperial College
518 London, UK); Rodrigo M Carrillo-Larco (Universidad Peruana Cayetano Heredia, Peru);
519 Shirin Djalalinia (Tehran University of Medical Sciences, Iran); Shahab Khatibzadeh
520 (Brandeis University, USA); Charles Lugero (Mulago Hospital, Uganda); Niloofar Peykari
521 (Tehran University of Medical Sciences, Iran); Wan Zhu Zhang (Uganda Heart Institute,
522 Uganda); Ver Bilano (Imperial College London, UK); Gretchen A Stevens (World Health
523 Organization, Switzerland); Melanie J Cowan (World Health Organization, Switzerland);
524 Leanne M Riley (World Health Organization, Switzerland); Prof Zhengming Chen
525 (University of Oxford, UK); Prof Ian R Hambleton (The University of the West Indies,
526 Barbados); Prof Rod T Jackson (University of Auckland, New Zealand); Prof Andre Pascal
527 Kengne (South African Medical Research Council, South Africa); Prof Young-Ho Khang
528 (Seoul National University, Republic of Korea); Prof Avula Laxmaiah (National Institute of
529 Nutrition, India); Jing Liu (Capital Medical University Beijing An Zhen Hospital, China);
530 Prof Reza Malekzadeh (Tehran University of Medical Sciences, Iran); Hannelore K
531 Neuhauser (Robert Koch Institute, Germany); Maroje Sorić (University of Zagreb, Croatia);
532 Gregor Starc (University of Ljubljana, Slovenia); Prof Johan Sundström (Uppsala University,
533 Sweden); Prof Mark Woodward (University of New South Wales, Australia; University of
534 Oxford, UK); Prof Majid Ezzati (Imperial College London, UK)

535

536

537 Country and Regional Data (* equal contribution; listed alphabetically)

538 Leandra Abarca-Gómez (Caja Costarricense de Seguro Social, Costa Rica)*; Ziad A Abdeen
539 (Al-Quds University, Palestine)*; Niveen M Abu-Rmeileh (Birzeit University, Palestine)*;
540 Benjamin Acosta-Cazares (Instituto Mexicano del Seguro Social, Mexico)*; Robert Adams
541 (The University of Adelaide, Australia)*; Wichai Aekplakorn (Mahidol University,
542 Thailand)*; Kaosar Afsana (BRAC, Bangladesh)*; Carlos A Aguilar-Salinas (Instituto
543 Nacional de Ciencias Médicas y Nutricion, Mexico)*; Charles Agyemang (University of
544 Amsterdam, The Netherlands)*; Alireza Ahmadvand (Non-Communicable Diseases
545 Research Center, Iran)*; Wolfgang Ahrens (Leibniz Institute for Prevention Research and
546 Epidemiology - BIPS, Germany)*; Kamel Ajlouni (National Center for Diabetes and
547 Endocrinology, Jordan)*; Nazgul Akhtaeva (Kazakh National Medical University,
548 Kazakhstan)*; Rajaa Al-Raddadi (Ministry of Health, Saudi Arabia)*; Mohamed M Ali
549 (World Health Organization, Switzerland)*; Osman Ali (Universiti Malaysia Sabah,
550 Malaysia)*; Ala'a Alkerwi (Luxembourg Institute of Health, Luxembourg)*; Eman Aly
551 (World Health Organization Regional Office for the Eastern Mediterranean, Egypt)*; Deepak
552 N Amarapurkar (Bombay Hospital and Medical Research Centre, India)*; Philippe Amouyel
553 (Lille University and Hospital, France)*; Antoinette Amuzu (London School of Hygiene &
554 Tropical Medicine, UK)*; Lars Bo Andersen (Western Norwegian University of Applied
555 Sciences, Norway)*; Sigmund A Anderssen (Norwegian School of Sport Sciences, Norway)*;
556 Lars H Ängquist (Bispebjerg and Frederiksberg Hospitals, Denmark)*; Ranjit Mohan Anjana
557 (Madras Diabetes Research Foundation, India)*; Daniel Ansong (Komfo Anokye Teaching
558 Hospital, Ghana)*; Hajar Aounallah-Skhiri (National Institute of Public Health, Tunisia)*;
559 Joana Araújo (Universidade do Porto, Portugal)*; Inger Ariansen (Norwegian Institute of
560 Public Health, Norway)*; Tahir Aris (Ministry of Health Malaysia, Malaysia)*; Nimmathota
561 Arlappa (Indian Council of Medical Research, India)*; Dominique Arveiler (Strasbourg

562 University and Hospital, France)*; Krishna K Aryal (Nepal Health Research Council,
563 Nepal)*; Thor Aspelund (Icelandic Heart Association, Iceland)*; Felix K Assah (University
564 of Yaoundé 1, Cameroon)*; Maria Cecília F Assunção (Federal University of Pelotas,
565 Brazil)*; Mária Avdicová (Regional Authority of Public Health, Banska Bystrica, Slovakia)*;
566 Ana Azevedo (University of Porto Medical School, Portugal)*; Fereidoun Azizi (Shahid
567 Beheshti University of Medical Sciences, Iran)*; Bontha V Babu (Indian Council of Medical
568 Research, India)*; Suhad Bahijri (King Abdulaziz University, Saudi Arabia)*; Nagalla
569 Balakrishna (Indian Council of Medical Research, India)*; Mohamed Bamoshmoosh
570 (University of Science and Technology, Yemen)*; Piotr Bandosz (Medical University of
571 Gdańsk, Poland)*; José R Banegas (Universidad Autónoma de Madrid, Spain)*; Carlo M
572 Barbagallo (University of Palermo, Italy)*; Alberto Barceló (Pan American Health
573 Organization, USA)*; Amina Barkat (Université Mohammed V de Rabat, Morocco)*;
574 Aluisio JD Barros (Federal University of Pelotas, Brazil)*; Mauro V Barros (University of
575 Pernambuco, Brazil)*; Iqbal Bata (Dalhousie University, Canada)*; Anwar M Batieha
576 (Jordan University of Science and Technology, Jordan)*; Assembekov Batyrbek (Kazakh
577 National Medical University, Kazakhstan)*; Louise A Baur (University of Sydney,
578 Australia)*; Robert Beaglehole (University of Auckland, New Zealand)*; Habiba Ben
579 Romdhane (University Tunis El Manar, Tunisia)*; Mikhail Benet (University Medical
580 Science, Cuba)*; Lowell S Benson (University of Utah School of Medicine, USA)*; Antonio
581 Bernabe-Ortiz (Universidad Peruana Cayetano Heredia, Peru)*; Gailute Bernotiene
582 (Lithuanian University of Health Sciences, Lithuania)*; Heloisa Bettoli (University of São
583 Paulo, Brazil)*; Aroor Bhagyalaxmi (B. J. Medical College, India)*; Sumit Bharadwaj
584 (Chirayu Medical College, India)*; Santosh K Bhargava (SL Jain Hospital, India)*; Yufang
585 Bi (Shanghai Jiao-Tong University School of Medicine, China)*; Mukharram Bikbov (Ufa
586 Eye Research Institute, Russia)*; Bihungum Bista (Nepal Health Research Council, Nepal)*;

587 Peter Bjerregaard (University of Southern Denmark, Denmark; University of Greenland,
588 Greenland)*; Espen Bjertness (University of Oslo, Norway)*; Marius B Bjertness (University
589 of Oslo, Norway)*; Cecilia Björkelund (University of Gothenburg, Sweden)*; Anneke
590 Blokstra (National Institute for Public Health and the Environment, The Netherlands)*;
591 Simona Bo (University of Turin, Italy)*; Martin Bobak (University College London, UK)*;
592 Heiner Boeing (German Institute of Human Nutrition, Germany)*; Jose G Boggia
593 (Universidad de la República, Uruguay)*; Carlos P Boissonnet (CEMIC, Argentina)*;
594 Vanina Bongard (Toulouse University School of Medicine, France)*; Rossana Borchini
595 (University Hospital of Varese, Italy)*; Pascal Bovet (Ministry of Health, Seychelles;
596 University of Lausanne, Switzerland)*; Lutgart Braeckman (Ghent University, Belgium)*;
597 Imperia Brajkovich (Universidad Central de Venezuela, Venezuela)*; Francesco Branca
598 (World Health Organization, Switzerland)*; Juergen Breckenkamp (Bielefeld University,
599 Germany)*; Hermann Brenner (German Cancer Research Center, Germany)*; Lizzy M
600 Brewster (University of Amsterdam, The Netherlands)*; Graziella Bruno (University of
601 Turin, Italy)*; H.B(as) Bueno-de-Mesquita (National Institute for Public Health and the
602 Environment, The Netherlands)*; Anna Bugge (University of Southern Denmark, Denmark)*;
603 Con Burns (Cork Institute of Technology, Ireland)*; Michael Bursztyn (Hadassah-Hebrew
604 University Medical Center, Israel)*; Antonio Cabrera de León (Universidad de La Laguna,
605 Spain)*; Joseph Cacciottolo (University of Malta, Malta)*; Hui Cai (Vanderbilt University,
606 USA)*; Christine Cameron (Canadian Fitness and Lifestyle Research Institute, Canada)*;
607 Günay Can (Istanbul University, Turkey)*; Ana Paula C Cândido (Universidade Federal de
608 Juiz de Fora, Brazil)*; Vincenzo Capuano (Cardiologia di Mercato S. Severino, Italy)*;
609 Viviane C Cardoso (University of São Paulo, Brazil)*; Axel C Carlsson (Karolinska Institutet,
610 Sweden)*; Maria J Carvalho (University of Porto, Portugal)*; Felipe F Casanueva (Santiago
611 de Compostela University, Spain)*; Juan-Pablo Casas (University College London, UK)*;

612 Carmelo A Caserta (Associazione Calabrese di Epatologia, Italy)*; Snehalatha Chamukuttan
613 (India Diabetes Research Foundation, India)*; Angelique W Chan (Duke-NUS Medical
614 School, Singapore)*; Queenie Chan (Imperial College London, UK)*; Himanshu K
615 Chaturvedi (National Institute of Medical Statistics, India)*; Nishi Chaturvedi (University
616 College London, UK)*; Chien-Jen Chen (Academia Sinica, Taiwan)*; Fangfang Chen
617 (Capital Institute of Pediatrics, China)*; Huashuai Chen (Duke University, USA)*; Shuohua
618 Chen (Kailuan General Hospital, China)*; Zhengming Chen (University of Oxford, UK)*;
619 Ching-Yu Cheng (Duke-NUS Medical School, Singapore)*; Imane Cherkaoui Dekkaki
620 (Université Mohammed V de Rabat, Morocco)*; Angela Chetrit (The Gertner Institute for
621 Epidemiology and Health Policy Research, Israel)*; Arnaud Chiolero (University of Bern,
622 Switzerland)*; Shu-Ti Chiou (Ministry of Health and Welfare, Taiwan)*; Adela Chirita-
623 Emandi (Victor Babes University of Medicine and Pharmacy, Romania)*; María-Dolores
624 Chirlaque (Murcia Regional Health Council, Spain)*; Belong Cho (Seoul National University
625 College of Medicine, South Korea)*; Yumi Cho (Korea Centers for Disease Control and
626 Prevention, South Korea)*; Jerzy Chudek (Medical University of Silesia, Poland)*; Renata
627 Cifkova (Charles University in Prague, Czech Republic)*; Eliza Cintezá (Carol Davila
628 University of Medicine and Pharmacy, Romania)*; Frank Claessens (Katholieke Universiteit
629 Leuven, Belgium)*; Els Clays (Ghent University, Belgium)*; Hans Concin (Agency for
630 Preventive and Social Medicine, Austria)*; Cyrus Cooper (University of Southampton, UK)*;
631 Rachel Cooper (University College London, UK)*; Tara C Coppinger (Cork Institute of
632 Technology, Ireland)*; Simona Costanzo (IRCCS Istituto Neurologico Mediterraneo
633 Neuromed, Italy)*; Dominique Cottel (Institut Pasteur de Lille, France)*; Chris Cowell
634 (University of Sydney, Australia)*; Cora L Craig (Canadian Fitness and Lifestyle Research
635 Institute, Canada)*; Ana B Crujeiras (CIBEROBN, Spain)*; Juan J Cruz (Universidad
636 Autónoma de Madrid, Spain)*; Graziella D'Arrigo (National Council of Research, Italy)*;

637 Eleonora d'Orsi (Universidade Federal de Santa Catarina, Brazil)*; Jean Dallongeville
638 (Institut Pasteur de Lille, France)*; Albertino Damasceno (Eduardo Mondlane University,
639 Mozambique)*; Goodarz Danaei (Harvard TH Chan School of Public Health, USA)*; Rachel
640 Dankner (The Gertner Institute for Epidemiology and Health Policy Research, Israel)*;
641 Thomas M Dantoft (Research Centre for Prevention and Health, Denmark)*; Luc Dauchet
642 (Lille University Hospital, France)*; Kairat Davletov (Kazakh National Medical University,
643 Kazakhstan)*; Guy De Backer (Ghent University, Belgium)*; Dirk De Bacquer (Ghent
644 University, Belgium)*; Mauro VG de Barros (University of Pernambuco, Brazil)*; Giovanni
645 de Gaetano (IRCCS Istituto Neurologico Mediterraneo Neuromed, Italy)*; Stefaan De
646 Henuau (Ghent University, Belgium)*; Paula Duarte de Oliveira (Federal University of
647 Pelotas, Brazil)*; Delphine De Smedt (Ghent University, Belgium)*; Mohan Deepa (Madras
648 Diabetes Research Foundation, India)*; Abbas Dehghan (Erasmus Medical Center Rotterdam,
649 The Netherlands)*; Hélène Delisle (University of Montreal, Canada)*; Valérie Deschamps
650 (French Public Health Agency, France)*; Klodian Dhana (Erasmus Medical Center
651 Rotterdam, The Netherlands)*; Augusto F Di Castelnuovo (IRCCS Istituto Neurologico
652 Mediterraneo Neuromed, Italy)*; Juvenal Soares Dias-da-Costa (Universidade do Vale do
653 Rio dos Sinos, Brazil)*; Alejandro Diaz (National Council of Scientific and Technical
654 Research, Argentina)*; Ty T Dickerson (University of Utah School of Medicine, USA)*;
655 Shirin Djalalinia (Non-Communicable Diseases Research Center, Iran)*; Ha TP Do (National
656 Institute of Nutrition, Vietnam)*; Annette J Dobson (University of Queensland, Australia)*;
657 Chiara Donfrancesco (Istituto Superiore di Sanità, Italy)*; Silvana P Donoso (Universidad de
658 Cuenca, Ecuador)*; Angela Döring (Helmholtz Zentrum München, Germany)*; Maria
659 Dorobantu (Carol Davila University of Medicine and Pharmacy, Romania)*; Kouamelan
660 Doua (Ministère de la Santé et de la Lutte Contre le Sida, Côte d'Ivoire)*; Wojciech Drygas
661 (The Cardinal Wyszynski Institute of Cardiology, Poland)*; Virginija Dulskiene (Lithuanian

662 University of Health Sciences, Lithuania)*; Aleksandar Džakula (University of Zagreb,
663 Croatia)*; Vilnis Dzerve (University of Latvia, Latvia)*; Elzbieta Dziankowska-Zaborszczyk
664 (Medical University of Lodz, Poland)*; Robert Eggertsen (University of Gothenburg,
665 Sweden)*; Ulf Ekelund (Norwegian School of Sport Sciences, Norway)*; Jalila El Ati
666 (National Institute of Nutrition and Food Technology, Tunisia)*; Paul Elliott (Imperial
667 College London, UK)*; Roberto Elosua (Institut Hospital del Mar d'Investigacions Mèdiques,
668 Spain)*; Rajiv T Erasmus (University of Stellenbosch, South Africa)*; Cihangir Erem
669 (Karadeniz Technical University, Turkey)*; Louise Eriksen (University of Southern Denmark,
670 Denmark)*; Jorge Escobedo-de la Peña (Instituto Mexicano del Seguro Social, Mexico)*;
671 Alun Evans (The Queen's University of Belfast, UK)*; David Faeh (University of Zurich,
672 Switzerland)*; Caroline H Fall (University of Southampton, UK)*; Farshad Farzadfar
673 (Tehran University of Medical Sciences, Iran)*; Francisco J Felix-Redondo (Centro de Salud
674 Villanueva Norte, Spain)*; Trevor S Ferguson (The University of the West Indies, Jamaica)*;
675 Daniel Fernández-Bergés (Hospital Don Benito-Villanueva de la Serena, Spain)*; Daniel
676 Ferrante (Ministry of Health, Argentina)*; Marika Ferrari (Council for Agricultural Research
677 and Economics, Italy)*; Catterina Ferreccio (Pontificia Universidad Católica de Chile,
678 Chile)*; Jean Ferrieres (Toulouse University School of Medicine, France)*; Joseph D Finn
679 (University of Manchester, UK)*; Krista Fischer (University of Tartu, Estonia)*; Bernhard
680 Föger (Agency for Preventive and Social Medicine, Austria)*; Leng Huat Foo (Universiti
681 Sains Malaysia, Malaysia)*; Ann-Sofie Forslund (Umeå University, Sweden)*; Maria
682 Forsner (Dalarna University, Sweden)*; Heba M Fouad (World Health Organization
683 Regional Office for the Eastern Mediterranean, Egypt)*; Damian K Francis (The University
684 of the West Indies, Jamaica)*; Maria do Carmo Franco (Federal University of São Paulo,
685 Brazil)*; Oscar H Franco (Erasmus Medical Center Rotterdam, The Netherlands)*;
686 Guillermo Frontera (Hospital Universitario Son Espases, Spain)*; Flavio D Fuchs (Hospital

687 de Clinicas de Porto Alegre, Brazil)*; Sandra C Fuchs (Universidade Federal do Rio Grande
688 do Sul, Brazil)*; Yuki Fujita (Kindai University, Japan)*; Takuro Furusawa (Kyoto
689 University, Japan)*; Zbigniew Gaciong (Medical University of Warsaw, Poland)*; Fabio
690 Galvano (University of Catania, Italy)*; Manoli Garcia-de-la-Hera (CIBER en Epidemiología
691 y Salud Pública, Spain)*; Dickman Gareta (University of KwaZulu-Natal, South Africa)*;
692 Sarah P Garnett (University of Sydney, Australia)*; Jean-Michel Gaspoz (Geneva University
693 Hospitals, Switzerland)*; Magda Gasull (CIBER en Epidemiología y Salud Pública, Spain)*;
694 Louise Gates (Australian Bureau of Statistics, Australia)*; Johanna M Geleijnse
695 (Wageningen University, The Netherlands)*; Anoosheh Ghasemian (Non-Communicable
696 Diseases Research Center, Iran)*; Anup Ghimire (B P Koirala Institute of Health Sciences,
697 Nepal)*; Simona Giampaoli (Istituto Superiore di Sanità, Italy)*; Francesco Gianfagna
698 (University of Insubria, Italy)*; Jonathan Giovannelli (Lille University Hospital, France)*;
699 Rebecca A Goldsmith (Ministry of Health, Israel)*; Helen Gonçalves (Federal University of
700 Pelotas, Brazil)*; Juan P González-Rivas (The Andes Clinic of Cardio-Metabolic Studies,
701 Venezuela)*; Marcela Gonzalez Gross (Universidad Politécnica de Madrid, Spain)*; Mariano
702 Bonet Gorbea (National Institute of Hygiene, Epidemiology and Microbiology, Cuba)*;
703 Frederic Gottrand (Université de Lille 2, France)*; Sidsel Graff-Iversen (Norwegian Institute
704 of Public Health, Norway)*; Dušan Grafnetter (Institute for Clinical and Experimental
705 Medicine, Czech Republic)*; Aneta Grajda (The Children's Memorial Health Institute,
706 Poland)*; Ronald D Gregor (Dalhousie University, Canada)*; Tomasz Grodzicki
707 (Jagiellonian University Medical College, Poland)*; Anders Grøntved (University of
708 Southern Denmark, Denmark)*; Giuseppe Grosso (Azienda Ospedaliera Universitaria
709 Policlinico Vittorio Emanuele, Italy)*; Gabriella Gruden (University of Turin, Italy)*; Vera
710 Grujic (University of Novi Sad, Serbia)*; Dongfeng Gu (National Center of Cardiovascular
711 Diseases, China)*; Ong Peng Guan (Singapore Eye Research Institute, Singapore)*; Elias F

712 Gudmundsson (Icelandic Heart Association, Iceland)*; Vilmundur Gudnason (University of
713 Iceland, Iceland)*; Ramiro Guerrero (Universidad Icesi, Colombia)*; Idris Guessous (Geneva
714 University Hospitals, Switzerland)*; Andre L Guimaraes (State University of Montes Claros,
715 Brazil)*; Martin C Gulliford (King's College London, UK)*; Johanna Gunnlaugsdottir
716 (Icelandic Heart Association, Iceland)*; Marc Gunter (Imperial College London, UK)*;
717 Prakash C Gupta (Healis-Sekhsaria Institute for Public Health, India)*; Rajeev Gupta
718 (Eternal Heart Care Centre & Research Institute, India)*; Oye Gureje (University of Ibadan,
719 Nigeria)*; Beata Gurzkowska (The Children's Memorial Health Institute, Poland)*; Laura
720 Gutierrez (Institute for Clinical Effectiveness and Health Policy, Argentina)*; Felix
721 Gutzwiller (University of Zurich, Switzerland)*; Farzad Hadaegh (Shahid Beheshti
722 University of Medical Sciences, Iran)*; Khairil Azhar Haji Si-Ramlee (Ministry of Health,
723 Brunei)*; Jytte Halkjær (Danish Cancer Society Research Centre, Denmark)*; Ian R
724 Hambleton (The University of the West Indies, Barbados)*; Rebecca Hardy (University
725 College London, UK)*; Rachakulla Hari Kumar (Indian Council of Medical Research,
726 India)*; Jun Hata (Kyushu University, Japan)*; Alison J Hayes (University of Sydney,
727 Australia)*; Jiang He (Tulane University, USA)*; Marleen Elisabeth Hendriks (Academic
728 Medical Center of University of Amsterdam, The Netherlands)*; Ana Henriques
729 (Universidade do Porto, Portugal)*; Leticia Hernandez Cadena (National Institute of Public
730 Health, Mexico)*; Sauli Herrala (Oulu University Hospital, Finland)*; Ramin Heshmat
731 (Chronic Diseases Research Center, Iran)*; Ilpo Tapani Hiitaniemi (Imperial College
732 London, UK)*; Sai Yin Ho (University of Hong Kong, China)*; Suzanne C Ho (The Chinese
733 University of Hong Kong, China)*; Michael Hobbs (University of Western Australia,
734 Australia)*; Albert Hofman (Erasmus Medical Center Rotterdam, The Netherlands)*; Gonul
735 Horasan Dinc (Celal Bayar University, Turkey)*; Andrea RVR Horimoto (Heart Institute,
736 Brazil)*; Claudia M Hormiga (Fundación Oftalmológica de Santander, Colombia)*;

737 Bernardo L Horta (Federal University of Pelotas, Brazil)*; Leila Houti (University of Oran 1,
738 Algeria)*; Christina Howitt (The University of the West Indies, Barbados)*; Thein Thein
739 Htay (Independent Public Health Specialist, Myanmar)*; Aung Soe Htet (Ministry of Health,
740 Myanmar)*; Maung Maung Than Htike (Ministry of Health, Myanmar)*; Yonghua Hu
741 (Peking University, China)*; José María Huerta (CIBER en Epidemiología y Salud Pública,
742 Spain)*; Martijn Huisman (Amsterdam Public Health Institute, The Netherlands)*; Abdullatif
743 S Husseini (Birzeit University, Palestine)*; Inge Huybrechts (International Agency for
744 Research on Cancer, France)*; Nahla Hwalla (American University of Beirut, Lebanon)*;
745 Licia Iacoviello (IRCCS Istituto Neurologico Mediterraneo Neuromed, Italy)*; Anna G
746 Iannone (Cardiologia di Mercato S. Severino, Italy)*; Mohsen M Ibrahim (Cairo University,
747 Egypt)*; Nayu Ikeda (National Institute of Health and Nutrition, Japan)*; M Arfan Ikram
748 (Erasmus Medical Center Rotterdam, The Netherlands)*; Vilma E Irazola (Institute for
749 Clinical Effectiveness and Health Policy, Argentina)*; Muhammad Islam (Aga Khan
750 University, Pakistan)*; Aziz al-Safi Ismail (Universiti Sains Malaysia, Malaysia)*; Vanja
751 Ivkovic (UHC Zagreb, Croatia)*; Masanori Iwasaki (Niigata University, Japan)*; Rod T
752 Jackson (University of Auckland, New Zealand)*; Jeremy M Jacobs (Hadassah University
753 Medical Center, Israel)*; Hashem Jaddou (Jordan University of Science and Technology,
754 Jordan)*; Tazeen Jafar (Duke-NUS Medical School, Singapore)*; Konrad Jamrozik
755 (University of Adelaide, Australia; deceased)*; Imre Janszky (Norwegian University of
756 Science and Technology, Norway)*; Grazyna Jasinska (Jagiellonian University Medical
757 College, Poland)*; Ana Jelaković (UHC Zagreb, Croatia)*; Bojan Jelaković (University of
758 Zagreb School of Medicine, Croatia)*; Garry Jennings (Heart Foundation, Australia)*; Chao
759 Qiang Jiang (Guangzhou 12th Hospital, China)*; Michel Joffres (Simon Fraser University,
760 Canada)*; Mattias Johansson (International Agency for Research on Cancer, France)*; Jost B
761 Jonas (Ruprecht-Karls-University of Heidelberg, Germany)*; Torben Jørgensen (Research

762 Centre for Prevention and Health, Denmark)*; Pradeep Joshi (World Health Organization
763 Country Office, India)*; Anne Juolevi (National Institute for Health and Welfare, Finland)*;
764 Gregor Jurak (University of Ljubljana, Slovenia)*; Vesna Jureša (University of Zagreb,
765 Croatia)*; Rudolf Kaaks (German Cancer Research Center, Germany)*; Anthony Kafatos
766 (University of Crete, Greece)*; Ofra Kalter-Leibovici (The Gertner Institute for
767 Epidemiology and Health Policy Research, Israel)*; Nor Azmi Kamaruddin (Universiti
768 Kebangsaan Malaysia, Malaysia)*; Khem B Karki (Nepal Health Research Council, Nepal)*;
769 Amir Kasaeian (Tehran University of Medical Sciences, Iran)*; Norhayati Kassim (Ministry
770 of Health, Brunei)*; Joanne Katz (Johns Hopkins Bloomberg School of Public Health,
771 USA)*; Jussi Kauhanen (University of Eastern Finland, Finland)*; Prabhdeep Kaur (National
772 Institute of Epidemiology, India)*; Maryam Kavousi (Erasmus Medical Center Rotterdam,
773 The Netherlands)*; Gyulli Kazakbaeva (Ufa Eye Research Institute, Russia)*; Ulrich Keil
774 (University of Münster, Germany)*; Lital Keinan Boker (Israel Center for Disease Control,
775 Israel)*; Sirkka Keinänen-Kiukaanniemi (Oulu University Hospital, Finland)*; Roya
776 Kelishadi (Isfahan University of Medical Sciences, Iran)*; Han CG Kemper (VU University
777 Medical Center, The Netherlands)*; Andre P Kengne (South African Medical Research
778 Council, South Africa)*; Alina Kerimkulova (Kyrgyz State Medical Academy, Kyrgyzstan)*;
779 Mathilde Kersting (Research Institute of Child Nutrition, Germany)*; Timothy Key
780 (University of Oxford, UK)*; Yousef Saleh Khader (Jordan University of Science and
781 Technology, Jordan)*; Davood Khalili (Shahid Beheshti University of Medical Sciences,
782 Iran)*; Young-Ho Khang (Seoul National University, South Korea)*; Mohammad Khateeb
783 (National Center for Diabetes and Endocrinology, Jordan)*; Kay-Tee Khaw (University of
784 Cambridge, UK)*; Ursula Kiechl-Kohlendorfer (Medical University of Innsbruck, Austria)*;
785 Stefan Kiechl (Medical University of Innsbruck, Austria)*; Japhet Killewo (Muhimbili
786 University of Health and Allied Sciences, Tanzania)*; Jeongseon Kim (National Cancer

787 Center, South Korea)*; Magdalena Klimek, (Jagiellonian University Medical College,
788 Poland)*; Jurate Klumbiene (Lithuanian University of Health Sciences, Lithuania)*; Michael
789 Knoflach (Medical University of Innsbruck, Austria)*; Elin Kolle (Norwegian School of
790 Sport Sciences, Norway)*; Patrick Kolsteren (Institute of Tropical Medicine, Belgium)*;
791 Paul Korrovits (Tartu University Clinics, Estonia)*; Seppo Koskinen (National Institute for
792 Health and Welfare, Finland)*; Katsuyasu Kouda (Kindai University, Japan)*; Sudhir
793 Kowlessur (Ministry of Health and Quality of Life, Mauritius)*; Slawomir Koziel (Polish
794 Academy of Sciences Anthropology Unit in Wroclaw, Poland)*; Susi Kriemler (University of
795 Zürich, Switzerland)*; Peter Lund Kristensen (University of Southern Denmark, Denmark)*;
796 Steinar Krokstad (Norwegian University of Science and Technology, Norway)*; Daan
797 Kromhout (University of Groningen, The Netherlands)*; Herculina S Kruger (North-West
798 University, South Africa)*; Ruzena Kubinova (National Institute of Public Health, Czech
799 Republic)*; Renata Kuciene (Lithuanian University of Health Sciences, Lithuania)*; Diana
800 Kuh (University College London, UK)*; Urho M Kujala (University of Jyväskylä, Finland)*;
801 Krzysztof Kula (Medical University of Lodz, Poland)*; Zbigniew Kulaga (The Children's
802 Memorial Health Institute, Poland)*; R Krishna Kumar (Amrita Institute of Medical Sciences,
803 India)*; Paweł Kurjata (The Cardinal Wyszyński Institute of Cardiology, Poland)*;
804 Yadlapalli S Kusuma (All India Institute of Medical Sciences, India)*; Kari Kuulasmaa
805 (National Institute for Health and Welfare, Finland)*; Catherine Kyobutungi (African
806 Population and Health Research Center, Kenya)*; Tiina Laatikainen (National Institute for
807 Health and Welfare, Finland)*; Carl Lachat (Ghent University, Belgium)*; Tai Hing Lam
808 (University of Hong Kong, China)*; Orlando Landrove (Ministerio de Salud Pública, Cuba)*;
809 Vera Lanska (Institute for Clinical and Experimental Medicine, Czech Republic)*; Georg
810 Lappas (Sahlgrenska Academy, Sweden)*; Bagher Larijani (Endocrinology and Metabolism
811 Research Center, Iran)*; Lars E Laugsand (Norwegian University of Science and Technology,

812 Norway)*; Avula Laxmaiah (Indian Council of Medical Research, India)*; Khanh Le
813 Nguyen Bao (National Institute of Nutrition, Vietnam)*; Tuyen D Le (National Institute of
814 Nutrition, Vietnam)*; Catherine Leclercq (Food and Agriculture Organization, Italy)*;
815 Jeannette Lee (National University of Singapore, Singapore)*; Jeonghee Lee (National
816 Cancer Center, South Korea)*; Terho Lehtimäki (Tampere University Hospital, Finland)*;
817 Luz M León-Muñoz (Universidad Autónoma de Madrid, Spain)*; Naomi S Levitt (University
818 of Cape Town, South Africa)*; Yanping Li (Harvard TH Chan School of Public Health,
819 USA)*; Christa L Lilly (West Virginia University, USA)*; Wei-Yen Lim (National
820 University of Singapore, Singapore)*; M Fernanda Lima-Costa (Oswaldo Cruz Foundation
821 Rene Rachou Research Institute, Brazil)*; Hsien-Ho Lin (National Taiwan University,
822 Taiwan)*; Xu Lin (University of Chinese Academy of Sciences, China)*; Allan Linneberg
823 (Research Centre for Prevention and Health, Denmark)*; Lauren Lissner (University of
824 Gothenburg, Sweden)*; Mieczyslaw Litwin (The Children's Memorial Health Institute,
825 Poland)*; Jing Liu (Capital Medical University Beijing An Zhen Hospital, China)*; Roberto
826 Lorbeer (University Medicine Greifswald, Germany)*; Paulo A Lotufo (University of São
827 Paulo, Brazil)*; José Eugenio Lozano (Consejería de Sanidad Junta de Castilla y León,
828 Spain)*; Dalia Luksiene (Lithuanian University of Health Sciences, Lithuania)*; Annamari
829 Lundqvist (National Institute for Health and Welfare, Finland)*; Nuno Lunet (Universidade
830 do Porto, Portugal)*; Per Lytsy (University of Uppsala, Sweden)*; Guansheng Ma (Peking
831 University, China)*; Jun Ma (Peking University, China)*; George LL Machado-Coelho
832 (Universidade Federal de Ouro Preto, Brazil)*; Suka Machi (The Jikei University School of
833 Medicine, Japan)*; Stefania Maggi (National Research Council, Italy)*; Dianna J Magliano
834 (Baker IDI Heart and Diabetes Institute, Australia)*; Emmanuella Magriplis (Agricultural
835 University of Athens, Greece)*; Marjeta Majer (University of Zagreb, Croatia)*; Marcia
836 Makdisse (Hospital Israelita Albert Einstein, Brazil)*; Reza Malekzadeh (Shiraz University

837 of Medical Sciences, Iran)*; Rahul Malhotra (Duke-NUS Medical School, Singapore)*;
838 Kodavanti Mallikharjuna Rao (Indian Council of Medical Research, India)*; Sofia Malyutina
839 (Institute of Internal and Preventive Medicine, Russia)*; Yannis Manios (Harokopio
840 University, Greece)*; Jim I Mann (University of Otago, New Zealand)*; Enzo Manzato
841 (University of Padova, Italy)*; Paula Margozzini (Pontificia Universidad Católica de Chile,
842 Chile)*; Pedro Marques-Vidal (Lausanne University Hospital, Switzerland)*; Larissa P
843 Marques (Universidade Federal de Santa Catarina, Brazil)*; Jaume Marrugat (Institut
844 Hospital del Mar d'Investigacions Mèdiques, Spain)*; Reynaldo Martorell (Emory University,
845 USA)*; Ellisiv B Mathiesen (UiT The Arctic University of Norway, Norway)*; Alicia
846 Matijasevich (University of São Paulo, Brazil)*; Tandi E Matsha (Cape Peninsula University
847 of Technology, South Africa)*; Jean Claude N Mbanya (University of Yaoundé 1,
848 Cameroon)*; Anselmo J Mc Donald Posso (Gorgas Memorial Institute of Health Studies,
849 Panama)*; Shelly R McFarlane (The University of the West Indies, Jamaica)*; Stephen T
850 McGarvey (Brown University, USA)*; Stela McLachlan (University of Edinburgh, UK)*;
851 Rachael M McLean (University of Otago, New Zealand)*; Scott B McLean (Statistics
852 Canada, Canada)*; Breige A McNulty (University College Dublin, Ireland)*; Sounnia
853 Mediene-Benckor (University of Oran 1, Algeria)*; Jurate Medzioniene (Lithuanian
854 University of Health Sciences, Lithuania)*; Aline Meirhaeghe (Institut National de la Santé
855 et de la Recherche Médicale, France)*; Christa Meisinger (Helmholtz Zentrum München,
856 Germany)*; Ana Maria B Menezes (Federal University of Pelotas, Brazil)*; Geetha R Menon
857 (Indian Council of Medical Research, India)*; Indrapal I Meshram (Indian Council of
858 Medical Research, India)*; Andres Metspalu (University of Tartu, Estonia)*; Haakon E
859 Meyer (University of Oslo, Norway)*; Jie Mi (Capital Institute of Pediatrics, China)*; Kairit
860 Mikkel (University of Tartu, Estonia)*; Jody C Miller (University of Otago, New Zealand)*;
861 Juan Francisco Miquel (Pontificia Universidad Católica de Chile, Chile)*; J Jaime Miranda

862 (Universidad Peruana Cayetano Heredia, Peru)*; Erkin Mirrakhimov (Kyrgyz State Medical
863 Academy, Kyrgyzstan)*; Marjeta Mišigoj-Durakovic (University of Zagreb, Croatia)*; Pietro
864 A Modesti (Universita' degli Studi di Firenze, Italy)*; Mostafa K Mohamed (Ain Shams
865 University, Egypt)*; Kazem Mohammad (Tehran University of Medical Sciences, Iran)*;
866 Noushin Mohammadifard (Hypertension Research Center, Iran)*; Viswanathan Mohan
867 (Madras Diabetes Research Foundation, India)*; Salim Mohanna (Universidad Peruana
868 Cayetano Heredia, Peru)*; Muhammad Fadhli Mohd Yusoff (Ministry of Health Malaysia,
869 Malaysia)*; Niels C Møller (University of Southern Denmark, Denmark)*; Dénes Molnár
870 (University of Pécs, Hungary)*; Amirabbas Momenan (Shahid Beheshti University of
871 Medical Sciences, Iran)*; Charles K Mondo (Mulago Hospital, Uganda)*; Kotsedi Daniel K
872 Monyeki (University of Limpopo, South Africa)*; Leila B Moreira (Universidade Federal do
873 Rio Grande do Sul, Brazil)*; Alain Morejon (University Medical Science, Cuba)*; Luis A
874 Moreno (Universidad de Zaragoza, Spain)*; Karen Morgan (RCSI Dublin, Ireland)*; George
875 Moschonis (Harokopio University, Greece)*; Małgorzata Mossakowska (International
876 Institute of Molecular and Cell Biology, Poland)*; Aya Mostafa (Ain Shams University,
877 Egypt)*; Jorge Mota (University of Porto, Portugal)*; Mohammad Esmaeel Motlagh (Ahvaz
878 Jundishapur University of Medical Sciences, Iran)*; Jorge Motta (Gorgas Memorial Institute
879 of Public Health, Panama)*; Thet Thet Mu (Department of Public Health, Myanmar)*; Maria
880 L Muiesan (University of Brescia, Italy)*; Martina Müller-Nurasyid (Helmholtz Zentrum
881 München, Germany)*; Neil Murphy (Imperial College London, UK)*; Jaakko Mursu
882 (University of Eastern Finland, Finland)*; Vera Musil (University of Zagreb, Croatia)*; Iraj
883 Nabipour (Bushehr University of Medical Sciences, Iran)*; Gabriele Nagel (Ulm University,
884 Germany)*; Balkish M Naidu (Institute of Public Health, Malaysia)*; Harunobu Nakamura
885 (Kobe University, Japan)*; Jana Námešná (Regional Authority of Public Health, Banska
886 Bystrica, Slovakia)*; Ei Ei K Nang (National University of Singapore, Singapore)*; Vinay B

887 Nangia (Suraj Eye Institute, India)*; Sameer Narake (Healis-Sekhsaria Institute for Public
888 Health, India)*; Eva Maria Navarrete-Muñoz (CIBER en Epidemiología y Salud Pública,
889 Spain)*; Ndeye Coumba Ndiaye (INSERM, France)*; William A Neal (West Virginia
890 University, USA)*; Martin Neovius (Karolinska Institutet, Sweden)*; Flavio Nervi
891 (Pontificia Universidad Católica de Chile, Chile)*; Hannelore K Neuhauser (Robert Koch
892 Institute, Germany)*; Chung T Nguyen (National Institute of Hygiene and Epidemiology,
893 Vietnam)*; Nguyen D Nguyen (The University of Pharmacy and Medicine of Ho Chi Minh
894 City, Vietnam)*; Quang Ngoc Nguyen (Hanoi Medical University, Vietnam)*; Ramfis E
895 Nieto-Martínez (Miami Veterans Affairs Healthcare System, USA)*; Teemu J Niiranen
896 (National Institute for Health and Welfare, Finland)*; Guang Ning (Shanghai Jiao-Tong
897 University School of Medicine, China)*; Toshiharu Ninomiya (Kyushu University, Japan)*;
898 Sania Nishtar (Heartfile, Pakistan)*; Marianna Noale (National Research Council, Italy)*;
899 Oscar A Noboa (Universidad de la República, Uruguay)*; Ahmad Ali Noorbala (Tehran
900 University of Medical Sciences, Iran)*; Teresa Norat (Imperial College London, UK)*;
901 Davide Noto (University of Palermo, Italy)*; Mohannad Al Nsour (Eastern Mediterranean
902 Public Health Network, Jordan)*; Dermot O'Reilly (The Queen's University of Belfast, UK)*;
903 Eiji Oda (Tachikawa General Hospital, Japan)*; Glenn Oehlers (Academic Hospital of
904 Paramaribo, Suriname)*; Kyungwon Oh (Korea Centers for Disease Control and Prevention,
905 South Korea)*; Kumiko Ohara (Kobe University, Japan)*; Maria Teresa A Olinto
906 (Universidade do Vale do Rio dos Sinos, Brazil)*; Isabel O Oliveira (Federal University of
907 Pelotas, Brazil)*; Mohd Azahadi Omar (Ministry of Health Malaysia, Malaysia)*; Altan Onat
908 (Istanbul University, Turkey)*; Sok King Ong (Ministry of Health, Brunei)*; Lariane M Ono
909 (Universidade Federal de Santa Catarina, Brazil)*; Pedro Ordunez (Pan American Health
910 Organization, USA)*; Rui Ornelas (University of Madeira, Portugal)*; Clive Osmond (MRC
911 Lifecourse Epidemiology Unit, UK)*; Sergej M Ostojic (University of Novi Sad, Serbia)*;

912 Afshin Ostovar (Bushehr University of Medical Sciences, Iran)*; Johanna A Otero
913 (Fundación Oftalmológica de Santander, Colombia)*; Kim Overvad (Aarhus University,
914 Denmark)*; Ellis Owusu-Dabo (Kwame Nkrumah University of Science and Technology,
915 Ghana)*; Fred Michel Paccaud (Institute for Social and Preventive Medicine, Switzerland)*;
916 Cristina Padez (University of Coimbra, Portugal)*; Elena Pahomova (University of Latvia,
917 Latvia)*; Andrzej Pajak (Jagiellonian University Medical College, Poland)*; Domenico Palli
918 (Cancer Prevention and Research Institute, Italy)*; Luigi Palmieri (Istituto Superiore di
919 Sanità, Italy)*; Wen-Harn Pan (Academia Sinica, Taiwan)*; Songhomitra Panda-Jonas
920 (Ruprecht-Karls-University of Heidelberg, Germany)*; Francesco Panza (IRCCS Casa
921 Sollievo della Sofferenza, Italy)*; Dimitrios Papandreou (Zayed University, UAE)*;
922 Winsome R Parnell (University of Otago, New Zealand)*; Mahboubeh Parsaeian (Tehran
923 University of Medical Sciences, Iran)*; Nikhil D Patel (Jivandep Hospital, India)*; Ivan
924 Pecin (University of Zagreb School of Medicine, Croatia; University Hospital Centre Zagreb,
925 Croatia)*; Mangesh S Pednekar (Healis-Sekhsaria Institute for Public Health, India)*;
926 Nasheeta Peer (South African Medical Research Council, South Africa)*; Petra H Peeters
927 (University Medical Center Utrecht, The Netherlands)*; Sergio Viana Peixoto (Oswaldo
928 Cruz Foundation Rene Rachou Research Institute, Brazil)*; Markku Peltonen (National
929 Institute for Health and Welfare, Finland)*; Alexandre C Pereira (Heart Institute, Brazil)*;
930 Annette Peters (Helmholtz Zentrum München, Germany)*; Janina Petkeviciene (Lithuanian
931 University of Health Sciences, Lithuania)*; Niloofar Peykari (Non-Communicable Diseases
932 Research Center, Iran)*; Son Thai Pham (Vietnam National Heart Institute, Vietnam)*; Iris
933 Pigeot (Leibniz Institute for Prevention Research and Epidemiology - BIPS, Germany)*;
934 Hynek Pikhart (University College London, UK)*; Aida Pilav (Federal Ministry of Health,
935 Bosnia and Herzegovina)*; Lorenza Pilotto (Centro di Prevenzione Cardiovascolare Udine,
936 Italy)*; Freda Pitakaka (Ministry of Health and Medical Services, Solomon Islands)*;

937 Aleksandra Piwonska (The Cardinal Wyszynski Institute of Cardiology, Poland)*; Pedro
938 Plans-Rubió (Public Health Agency of Catalonia, Spain)*; Ozren Polašek (University of Split,
939 Croatia)*; Miquel Porta (Institut Hospital del Mar d'Investigacions Mèdiques, Spain)*;
940 Marileen LP Portegies (Erasmus Medical Center Rotterdam, The Netherlands)*; Akram
941 Pourshams (Digestive Disease Research Institute, Iran)*; Hossein Poustchi (Digestive
942 Disease Research Institute, Iran)*; Rajendra Pradeepa (Madras Diabetes Research Foundation,
943 India)*; Mathur Prashant (Indian Council of Medical Research, India)*; Jacqueline F Price
944 (University of Edinburgh, UK)*; Jardena J Puder (Centre Hospitalier Universitaire Vaudois,
945 Switzerland)*; Maria Puiu (Victor Babes University of Medicine and Pharmacy, Romania)*;
946 Margus Punab (Tartu University Clinics, Estonia)*; Radwan F Qasrawi (Al-Quds University,
947 Palestine)*; Mostafa Qorbani (Alborz University of Medical Sciences, Iran)*; Tran Quoc Bao
948 (Ministry of Health, Vietnam)*; Ivana Radic (University of Novi Sad, Serbia)*; Ricardas
949 Radisauskas (Lithuanian University of Health Sciences, Lithuania)*; Mahfuzar Rahman
950 (BRAC, Bangladesh)*; Olli Raitakari (University of Turku, Finland)*; Manu Raj (Amrita
951 Institute of Medical Sciences, India)*; Sudha Ramachandra Rao (National Institute of
952 Epidemiology, India)*; Ambady Ramachandran (India Diabetes Research Foundation,
953 India)*; Elisabete Ramos (University of Porto Medical School, Portugal)*; Lekhraj Rampal
954 (Universiti Putra Malaysia, Malaysia)*; Sanjay Rampal (University of Malaya, Malaysia)*;
955 Daniel A Rangel Reina (Gorgas Memorial Institute of Health Studies, Panama)*; Josep
956 Redon (University of Valencia, Spain)*; Paul Ferdinand M Reganit (University of the
957 Philippines, Philippines)*; Robespierre Ribeiro (Minas Gerais State Secretariat for Health,
958 Brazil)*; Elio Riboli (Imperial College London, UK)*; Fernando Rigo (Health Center San
959 Agustín, Spain)*; Tobias F Rinke de Wit (PharmAccess Foundation, The Netherlands)*;
960 Raphael M Ritti-Dias (Hospital Israelita Albert Einstein, Brazil)*; Sian M Robinson
961 (University of Southampton, UK)*; Cynthia Robitaille (Public Health Agency of Canada,

962 Canada)*; Fernando Rodríguez-Artalejo (Universidad Autónoma de Madrid, Spain)*; María
963 del Cristo Rodriguez-Perez (Canarian Health Service, Spain)*; Laura A Rodríguez-
964 Villamizar (Universidad Industrial de Santander, Colombia)*; Rosalba Rojas-Martinez
965 (Instituto Nacional de Salud Pública, Mexico)*; Dora Romaguera (CIBEROBN, Spain)*;
966 Kimmo Ronkainen (University of Eastern Finland, Finland)*; Annika Rosengren (University
967 of Gothenburg, Sweden)*; Joel GR Roy (Statistics Canada, Canada)*; Adolfo Rubinstein
968 (Institute for Clinical Effectiveness and Health Policy, Argentina)*; Blanca Sandra Ruiz-
969 Betancourt (Instituto Mexicano del Seguro Social, Mexico)*; Marcin Rutkowski (Medical
970 University of Gdansk, Poland)*; Charumathi Sabanayagam (Singapore Eye Research
971 Institute, Singapore)*; Harshpal S Sachdev (Sitaram Bhartia Institute of Science and
972 Research, India)*; Olfa Saidi (University Tunis El Manar, Tunisia)*; Sibel Sakarya
973 (Marmara University, Turkey)*; Benoit Salanave (French Public Health Agency, France)*;
974 Eduardo Salazar Martinez (National Institute of Public Health, Mexico)*; Diego Salmerón
975 (CIBER de Epidemiología y Salud Pública, Spain)*; Veikko Salomaa (National Institute for
976 Health and Welfare, Finland)*; Jukka T Salonen (University of Helsinki, Finland)*; Massimo
977 Salvetti (University of Brescia, Italy)*; Jose Sánchez-Abanto (National Institute of Health,
978 Peru)*; Susana Sans (Catalan Department of Health, Spain)*; Diana A Santos (Universidade
979 de Lisboa, Portugal)*; Ina S Santos (Federal University of Pelotas, Brazil)*; Renata Nunes
980 dos Santos (University of Sao Paulo Clinics Hospital, Brazil)*; Rute Santos (University of
981 Porto, Portugal)*; Jouko L Saramies (South Karelia Social and Health Care District,
982 Finland)*; Luis B Sardinha (Universidade de Lisboa, Portugal)*; Giselle Sarganas(Robert
983 Koch Institute, Germany)*; Nizal Sarrafzadegan (Isfahan Cardiovascular Research Center,
984 Iran)*; Kai-Uwe Saum (German Cancer Research Center, Germany)*; Savvas Savva
985 (Research and Education Institute of Child Health, Cyprus)*; Marcia Scazufca (University of
986 Sao Paulo Clinics Hospital, Brazil)*; Herman Schargrodsky (Hospital Italiano de Buenos

987 Aires, Argentina)*; Constance Schultsz (Academic Medical Center of University of
988 Amsterdam, The Netherlands)*; Aletta E Schutte (South African Medical Research Council,
989 South Africa; North-West University, South Africa)*; Aye Aye Sein (Ministry of Health,
990 Myanmar)*; Abhijit Sen (Norwegian University of Science and Technology, Norway)*;
991 Idowu O Senbanjo (Lagos State University College of Medicine, Nigeria)*; Sadaf G
992 Sepanlou (Tehran University of Medical Sciences, Iran)*; Sanjib K Sharma (B P Koirala
993 Institute of Health Sciences, Nepal)*; Jonathan E Shaw (Baker IDI Heart and Diabetes
994 Institute, Australia)*; Kenji Shibuya (The University of Tokyo, Japan)*; Dong Wook Shin
995 (Samsung Medical Center, South Korea)*; Youchan Shin (Singapore Eye Research Institute,
996 Singapore)*; Rosalynn Siantar (Singapore Eye Research Institute, Singapore)*; Abla M Sibai
997 (American University of Beirut, Lebanon)*; Diego Augusto Santos Silva (Federal University
998 of Santa Catarina, Brazil)*; Mary Simon (India Diabetes Research Foundation, India)*;
999 Judith Simons (St Vincent's Hospital, Australia)*; Leon A Simons (University of New South
1000 Wales, Australia)*; Michael Sjöström (Karolinska Institutet, Sweden)*; Sine Skovbjerg
1001 (Research Centre for Prevention and Health, Denmark)*; Jolanta Slowikowska-Hilczer
1002 (Medical University of Lodz, Poland)*; Przemyslaw Slusarczyk (International Institute of
1003 Molecular and Cell Biology, Poland)*; Liam Smeeth (London School of Hygiene & Tropical
1004 Medicine, UK)*; Margaret C Smith (University of Oxford, UK)*; Marieke B Snijder
1005 (Academic Medical Center Amsterdam, The Netherlands)*; Hung-Kwan So (The Chinese
1006 University of Hong Kong, China)*; Eugène Sobngwi (University of Yaoundé 1, Cameroon)*;
1007 Stefan Söderberg (Umeå University, Sweden)*; Vincenzo Solfrizzi (University of Bari,
1008 Italy)*; Emily Sonestedt (Lund University, Sweden)*; Yi Song (Peking University, China)*;
1009 Thorkild IA Sørensen (University of Copenhagen, Denmark)*; Maroje Soric (University of
1010 Zagreb, Croatia)*; Charles Sossa Jérôme (Institut Régional de Santé Publique, Benin)*;
1011 Aicha Soumare (University of Bordeaux, France)*; Jan A Staessen (University of Leuven,

1012 Belgium)*; Gregor Starc (University of Ljubljana, Slovenia)*; Maria G Stathopoulou
1013 (INSERM, France)*; Bill Stavreski (Heart Foundation, Australia)*; Jostein Steene-
1014 Johannessen (Norwegian School of Sport Sciences, Norway)*; Peter Stehle (Bonn University,
1015 Germany)*; Aryeh D Stein (Emory University, USA)*; George S Stergiou (Sotiria Hospital,
1016 Greece)*; Jochanan Stessman (Hadassah University Medical Center, Israel)*; Jutta Stieber
1017 (Helmholtz Zentrum München, Germany; deceased)*; Doris Stöckl (Helmholtz Zentrum
1018 München, Germany)*; Tanja Stocks (Lund University, Sweden)*; Jakub Stokwiszewski
1019 (National Institute of Public Health-National Institute of Hygiene, Poland)*; Karien Stronks
1020 (University of Amsterdam, The Netherlands)*; Maria Wany Strufaldi (Federal University of
1021 São Paulo, Brazil)*; Chien-An Sun (Fu Jen Catholic University, Taiwan)*; Johan Sundström
1022 (Uppsala University, Sweden)*; Yn-Tz Sung (The Chinese University of Hong Kong,
1023 China)*; Paibul Suriyawongpaisal (Mahidol University, Thailand)*; Rody G Sy (University
1024 of the Philippines, Philippines)*; E Shyong Tai (National University of Singapore,
1025 Singapore)*; Mari-Liis Tammesoo (University of Tartu, Estonia)*; Abdonas Tamosiunas
1026 (Lithuanian University of Health Sciences, Lithuania)*; Eng Joo Tan (University of Sydney,
1027 Australia)*; Line Tang (Research Centre for Prevention and Health, Denmark)*; Xun Tang
1028 (Peking University, China)*; Frank Tanser (University of KwaZulu-Natal, South Africa)*;
1029 Yong Tao (Peking University, China)*; Mohammed Rasoul Tarawneh (Ministry of Health,
1030 Jordan)*; Carolina B Tarqui-Mamani (National Institute of Health, Peru)*; Oana-Florentina
1031 Tautu (Carol Davila University of Medicine and Pharmacy, Romania)*; Anne Taylor (The
1032 University of Adelaide, Australia)*; Holger Theobald (Karolinska Institutet, Sweden)*;
1033 Lutgarde Thijs (University of Leuven, Belgium)*; Betina H Thuesen (Research Centre for
1034 Prevention and Health, Denmark)*; Anne Tjonneland (Danish Cancer Society Research
1035 Centre, Denmark)*; Hanna K Tolonen (National Institute for Health and Welfare, Finland)*;
1036 Janne S Tolstrup (University of Southern Denmark, Denmark)*; Murat Topbas (Karadeniz

1037 Technical University, Turkey)*; Roman Topór-Madry (Jagiellonian University Medical
1038 College, Poland)*; María José Tormo (Health Service of Murcia, Spain)*; Maties Torrent
1039 (IB-SALUT Area de Salut de Menorca, Spain)*; Pierre Traissac (Institut de Recherche pour
1040 le Développement, France)*; Dimitrios Trichopoulos (Harvard TH Chan School of Public
1041 Health, USA; deceased)*; Antonia Trichopoulou (Hellenic Health Foundation, Greece)*;
1042 Oanh TH Trinh (The University of Pharmacy and Medicine of Ho Chi Minh City, Vietnam)*;
1043 Atul Trivedi (Government Medical College, India)*; Lechaba Tshepo (Sefako Makgatho
1044 Health Science University, South Africa)*; Marshall K Tulloch-Reid (The University of the
1045 West Indies, Jamaica)*; Fikru Tullu (Addis Ababa University, Ethiopia)*; Tomi-Pekka
1046 Tuomainen (University of Eastern Finland, Finland)*; Jaakko Tuomilehto (Dasman Diabetes
1047 Institute, Kuwait)*; Maria L Turley (Ministry of Health, New Zealand)*; Per Tynelius
1048 (Karolinska Institutet, Sweden)*; Christophe Tzourio (University of Bordeaux, France)*;
1049 Peter Ueda (Harvard TH Chan School of Public Health, USA)*; Eunice E Ugel (Universidad
1050 Centro-Occidental Lisandro Alvarado, Venezuela)*; Hanno Ulmer (Medical University of
1051 Innsbruck, Austria)*; Hannu MT Uusitalo (University of Tampere Tays Eye Center,
1052 Finland)*; Gonzalo Valdivia (Pontificia Universidad Católica de Chile, Chile)*; Damaskini
1053 Valvi (Harvard TH Chan School of Public Health, USA)*; Yvonne T van der Schouw
1054 (University Medical Center Utrecht, The Netherlands)*; Koen Van Herck (Ghent University,
1055 Belgium)*; Hoang Van Minh (Hanoi School of Public Health, Vietnam)*; Lenie van Rossem
1056 (University Medical Center Utrecht, The Netherlands)*; Natasja M Van Schoor (Amsterdam
1057 Public Health Institute, The Netherlands)*; Irene GM van Valkengoed (Academic Medical
1058 Center Amsterdam, The Netherlands)*; Dirk Vanderschueren (Katholieke Universiteit
1059 Leuven, Belgium)*; Diego Vanuzzo (Centro di Prevenzione Cardiovascolare Udine, Italy)*;
1060 Lars Vatten (Norwegian University of Science and Technology, Norway)*; Tomas Vega
1061 (Consejería de Sanidad Junta de Castilla y León, Spain)*; Gustavo Velasquez-Melendez

1062 (Universidade Federal de Minas Gerais, Brazil)*; Giovanni Veronesi (University of Insubria,
1063 Italy)*; WM Monique Verschuren (National Institute for Public Health and the Environment,
1064 The Netherlands)*; Roosmarijn Verstraeten (Institute of Tropical Medicine, Belgium)*;
1065 Cesar G Victora (Federal University of Pelotas, Brazil)*; Lucie Viet (National Institute for
1066 Public Health and the Environment, The Netherlands)*; Eira Viikari-Juntura (Finnish
1067 Institute of Occupational Health, Finland)*; Paolo Vineis (Imperial College London, UK)*;
1068 Jesus Vioque (Universidad Miguel Hernandez, Spain)*; Jyrki K Virtanen (University of
1069 Eastern Finland, Finland)*; Sophie Visvikis-Siest (INSERM, France)*; Bharathi
1070 Viswanathan (Ministry of Health, Seychelles)*; Tiina Vlasoff (North Karelian Center for
1071 Public Health, Finland)*; Peter Vollenweider (Lausanne University Hospital, Switzerland)*;
1072 Sari Voutilainen (University of Eastern Finland, Finland)*; Alisha N Wade (University of the
1073 Witwatersrand, South Africa)*; Aline Wagner (University of Strasbourg, France)*; Janette
1074 Walton (University College Cork, Ireland)*; Wan Mohamad Wan Bebakar (Universiti Sains
1075 Malaysia, Malaysia)*; Wan Nazaimoon Wan Mohamud (Institute for Medical Research,
1076 Malaysia)*; Rildo S Wanderley Jr. (University of Pernambuco, Brazil)*; Ming-Dong Wang
1077 (Public Health Agency of Canada, Canada)*; Qian Wang (Xinjiang Medical University,
1078 China)*; Ya Xing Wang (Capital Medical University, China)*; Ying-Wei Wang (Ministry of
1079 Health and Welfare, Taiwan)*; S Goya Wannamethee (University College London, UK)*;
1080 Nicholas Wareham (University of Cambridge, UK)*; Niels Wedderkopp (University of
1081 Southern Denmark, Denmark)*; Deepa Weerasekera (Ministry of Health, New Zealand)*;
1082 Peter H Whincup (St George's, University of London, UK)*; Kurt Widhalm (Medical
1083 University of Vienna, Austria)*; Indah S Widyahening (Universitas Indonesia, Indonesia)*;
1084 Andrzej Wiecek (Medical University of Silesia, Poland)*; Alet H Wijga (National Institute
1085 for Public Health and the Environment, The Netherlands)*; Rainford J Wilks (The University
1086 of the West Indies, Jamaica)*; Johann Willeit (Medical University of Innsbruck, Austria)*;

1087 Peter Willeit (Medical University of Innsbruck, Austria)*; Emmanuel A Williams (Komfo
1088 Anokye Teaching Hospital, Ghana)*; Tom Wilsgaard (UiT The Arctic University of Norway,
1089 Norway)*; Bogdan Wojtyniak (National Institute of Public Health-National Institute of
1090 Hygiene, Poland)*; Roy A Wong-McClure (Caja Costarricense de Seguro Social, Costa
1091 Rica)*; Tien Yin Wong (Duke-NUS Medical School, Singapore)*; Jean Woo (The Chinese
1092 University of Hong Kong, China)*; Mark Woodward (University of New South Wales,
1093 Australia; University of Oxford, UK)*; Aleksander Giwercman Wu (Lund University,
1094 Sweden)*; Frederick C Wu (University of Manchester, UK)*; Shouling Wu (Kailuan General
1095 Hospital, China)*; Haiquan Xu (Institute of Food and Nutrition Development of Ministry of
1096 Agriculture, China)*; Weili Yan (Children's Hospital of Fudan University, China)*;
1097 Xiaoguang Yang (Chinese Center for Disease Control and Prevention, China)*; Xingwang
1098 Ye (University of Chinese Academy of Sciences, China)*; Panayiotis K Yiallouros
1099 (University of Cyprus, Cyprus)*; Akihiro Yoshihara (Niigata University, Japan)*; Novie O
1100 Younger-Coleman (The University of the West Indies, Jamaica)*; Ahmad F Yusoff (Ministry
1101 of Health Malaysia, Malaysia)*; Muhammad Fadhli M Yusoff (Institute of Public Health,
1102 Malaysia)*; Sabina Zambon (University of Padova, Italy)*; Antonis Zampelas (Agricultural
1103 University of Athens, Greece)*; Tomasz Zdrojewski (Medical University of Gdansk,
1104 Poland)*; Yi Zeng (Duke University, USA; Peking University, China, USA)*; Dong Zhao
1105 (Capital Medical University Beijing An Zhen Hospital, China)*; Wenhua Zhao (Chinese
1106 Center for Disease Control and Prevention, China)*; Wei Zheng (Vanderbilt University,
1107 USA)*; Yingfeng Zheng (Singapore Eye Research Institute, Singapore)*; Dan Zhu (Inner
1108 Mongolia Medical University, China)*; Baurzhan Zhussupov (Kazakh National Medical
1109 University, Kazakhstan)*; Esther Zimmermann (Bispebjerg and Frederiksberg Hospitals,
1110 Denmark)*; Julio Zuñiga Cisneros (Gorgas Memorial Institute of Public Health, Panama)*